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SUMMARY
This paper uses meta-analysis of published data and a deterministic mathematical model of
hepatitis B virus (HBV) transmission to describe the patterns of HBV infection in high
endemicity areas. We describe the association between the prevalence of carriers and a simple
measure of the rate of infection, the age at which half the population have been infected (A50),
and assess the contribution of horizontal and perinatal transmission to this association. We
found that the two main hyper-endemic areas of sub-Saharan Africa and east Asia have similar
prevalences of carriers and values of A50, and that there is a negative nonlinear relationship
between A50 and the prevalence of carriers in high endemicity areas (Spearman's Rank, P =
0 0086). We quantified the risk of perinatal transmission and the age-dependent rate of
infection to allow a comparison between the main hyper-endemic areas. East Asia was found
to have higher prevalences of HBeAg positive mothers and a greater risk of perinatal
transmission from HBeAg positive mothers than sub-Saharan Africa, though the differences
were not statistically significant. However, the two areas have similar magnitudes and age-
dependent rates of horizontal transmission. Results of a simple compartmental model suggest
that similar rates of horizontal transmission are sufficient to generate the similar patterns
between A50 and the prevalences of carriers. Interrupting horizontal transmission by mass
immunization is expected to have a significant, nonlinear impact on the rate of acquisition of
new carriers.
INTRODUCTION
Infection with hepatitis B virus (HBV) poses a
significant public health problem in many parts of the
world, particularly in developing countries [1]. It has
been estimated that over 1 billion individuals have
evidence of exposure to HBV [2] and there are
approximately 300 million carriers of the virus, most
ofwhom come from east Asia and sub-Saharan Africa
[1]. Carriers of HBV have a high risk of developing
chronic liver disease such as cirrhosis or hepatocellular
carcinoma [3]. As many as 30% of carriers who
survive for 30 years or more may subsequently die of
the chronic sequelae of HBV infection [4]. Infection
by HBV can therefore be a major cause of morbidity
and mortality in areas, such as east Asia and sub-
Saharan Africa, that have high prevalences of carriers.
Whilst there is no currently available treatment for
carriers, infection can be prevented by immunization
with plasma-derived or recombinant vaccine. Both
vaccines are safe and effective [5], however they are
expensive compared to other vaccines commonly
given in childhood [1], they require multiple doses,
and vaccine induced specific antibody titres decline
over time [6-8]. To optimize the use of vaccination as
a means of controlling HBV a thorough under-
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standing of the epidemiology of the virus is required
as a prerequisite to assessing the direct and indirect
consequences of mass immunization.
The epidemiology of HBV varies greatly among
different areas of the world. It is, however, possible to
broadly classify geographical areas according to the
prevalence of HBV infection [4]. In areas with low
endemicity of the virus, such as North America and
northern Europe, transmission of HBV typically
occurs between adults via parenteral exposure or
sexual contact, and groups with high risk behaviours,
such as intra-venous drug users or homosexual men,
can be identified. In areas of high endemicity on the
other hand, such as east Asia and sub-Saharan Africa,
infection with HBV is not restricted to those with high
risk behaviours and infection primarily occurs during
childhood. This study focuses on the epidemiology of
HBV in highly endemic areas, which we define as a
region in which more than 75 % of the adult
population has serological evidence of past or current
infection with HBV. Worldwide the two principal
areas of high endemicity, in terms of the numbers of
people infected, are east Asia and sub-Saharan Africa
[1], and this paper concentrates on the epidemiology
of HBV in these areas.
There are two main features of HBV epidemiology
in highly endemic areas: a low average age at infection
and a high prevalence of carriers. These two variables
are dependent on one another as numerous studies
[9-11] have clearly shown a rapid decline in the
probability of developing the carrier state with
increasing age at infection. Approximately 90% of
infants become carriers if infected [12-14], whereas
10%, or less, of adults develop the carrier state if
infected [15-17]. This decline in the risk of developing
the carrier state with increasing age at infection is
highly nonlinear and appears to be remarkably
consistent for a wide range of communities and
geographical settings [18]. Childhood infection by
HBV occurs principally via 2 routes in developing
countries namely, perinatal transmission, which is
infection from an infectious mother to her infant
around the time of birth (within the first year), and
horizontal transmission which can be defined as
infection resulting from close contact which is not
perinatal and not sexual in nature. The definition of
horizontal transmission is vague and the mechanisms
by which the virus is transmitted are poorly under-
stood, though infection is thought to occur primarily
within the household and most frequently between
siblings [19, 20].
This paper reviews the patterns of HBV infection in
highly endemic countries and attempts to define the
epidemiological relationships between the routes of
infection, the age at infection and the prevalence of
carriers. This study aims to highlight those factors
which influence the pattern of HBV infection in highly
endemic zones, aid future data collection, and assist
further studies that aim to quantitatively predict the
impact of different control programmes.
The present study makes extensive use of published
serological surveys. A variety of host sub-populations
which differ in their HBV infection status can be
distinguished on the basis of specific serological
markers. Consequently, these markers are invaluable
for epidemiological research. The following is a
resume of the interpretation of serological markers
used throughout the text. The hepatitis B surface
antigen (HBsAg) is indicative of viral replication and
infectiousness. In acute patients who are able to
mount an effective response to HBV the levels of
HBsAg decline in the late convalescent period and
disappear after about 3 months [21, 22]. In carriers,
however, HBsAg remains detectable for long periods
of time and perhaps indefinitely (see later). Individ-
uals positive for HBsAg for greater than 6 months are
defined as carriers of the virus [23]. Antibody
produced against HBsAg due to either natural
infection or vaccination is termed anti-HBs. This
protective antibody is passively transferred from an
immune mother to her infant. Antibody to the viral
core antigen (anti-HBc) develops during the acute
phase of infection and seems to persist for the lifetime
of the individual [21, 24], it is therefore used as a
marker of past or present infection. The presence of
anti-HBc is sometimes the only detectable marker of
exposure to HBV [21, 24]. Anti-HBc is passed across
the placenta and is present in breast-milk, but it is not
a protective antibody. The early or e-antigen (HBeAg)
can be detected in the early phase of infection and is
rapidly cleared in acute infections. HBeAg may persist
in the serum of chronic HBsAg carriers for several
years. The presence of HBeAg correlates with high
infectivity and it is used as a marker of rapid viral
replication [25].
METHODS
Selection of surveys and interpretation of data
Data presented in this paper were obtained from an
extensive survey of the published literature. Surveys
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were selected for inclusion in this study based
primarily on the serological markers investigated.
Cross-sectional, serological surveys for HBV mar-
kers, finely stratified by age yield estimates of age-
dependent forces of infection and the magnitude of
HBV transmission within a community. Surveys were
included only if the proportion HBsAg positive and
anti-HBc positive had been recorded. Some 5-20% of
individuals previously infected with HBV are positive
for anti-HBc alone [24], therefore absence of this
marker from a study could lead to a significant
underestimate of infection rates. Hence those surveys
which did not measure anti-HBc were excluded from
the analysis. Twelve surveys covering 16 different
communities fitted the selection criteria. They in-
cluded surveys from The Gambia [26], Zambia [27],
Nairobi [28], Senegal [30], South Africa [31], Taiwan
[32], four surveys from the Philippines [33] and one
from Shanghai [34]. In addition to the surveys from
sub-Saharan Africa and east Asia, three more studies
from other highly endemic populations were included,
from French Polynesia [35], Solomon Islands [36] and
Venezuela [37]. A variety of serological tests were used
in the surveys for detection of serological markers.
However, the tests do not differ appreciably in
sensitivity and specificity for a particular marker
[38, 39], and this is therefore unlikely to be a significant
source of bias.
Hospital based surveys of pregnant women and
mother-infant pairs were used to estimate the
prevalence of serological markers in pregnant women
and the risk of perinatal transmission according to the
infection status of the mother. Note that we take
perinatal transmission to be infection of the infant by
the mother in the first year of life. Many of the
perinatal transmission studies pre-date the practice
of immunization of infants at risk of HBV infection,
and, as a result, the serological tests used may have
been older and less reliable than those used in the
cross-sectional surveys.
Statistical methods
The age at which half the sample population has
evidence of past or present infection, hereafter termed
A50, was chosen as a simple measure of the overall
magnitude or rate of infection within a community.
The value of A50 approximates to the median age at
infection if the proportion of the population with at
least one marker approaches 100% in the upper age
at infection as a marker of the rate of infection as it
can be interpolated directly from age-serological
profiles, whereas calculation of the mean age at
infection requires prior estimation of the underlying
forces of infection. A test for linearity in the
relationship between the value of A50 and the
prevalence of carriers, recorded in the surveys, was
performed in two ways. First, by residual analysis of
a linear regression model (Bartlett's three group
regression, which does not weight by sample size, was
chosen, as the independent variable, A50, was esti-
mated [40]). Second, the likelihood ratio test was used
to compare the fit of a linear and quadratic model to
the data. These models were fitted by maximum
likelihood which automatically weights by sample
size.
Differences in the prevalence ofHBsAg and HBeAg
positive pregnant mothers and the risk of transmission
to infants over the first year of life amongst different
geographical areas were investigated using multilevel
mixed effect models (MLn: Institute of Education,
University of London). Data on individuals' status for
each outcome measure was derived from several
studies. Based on location, studies were grouped into
broad geographical areas: sub-Saharan Africa, east
Asia, other developing countries and developed
countries. For each binary outcome, a multi-level
version of the logistic model was fitted. In the models,
the geographical area in which each study was
performed was treated as a fixed effect parameter,
while a single study-level random effect parameter was
incorporated to account for clustering of responses
within study location, i.e. the within area variation.
For the case in which data from three geographical
areas were used the full model can be written as:
logitYijk log ( 7Fk)+ e~
= bl(Africa)k + b2(Develop)k
+ b3(Asia)k + Ujk + eiJk,
where: Yjk is binary and denotes the observed value of
the response variable for the ith individual in the jth
study location in the kth geographical area; Tijk is the
probability of an individual's outcome measure being
positive; b1, b2 and b3 are the fixed effect estimates for
sub-Saharan Africa, other developing countries and
east Asia respectively; Uj denotes the departure of the
jth study mean from its corresponding kth area mean
estimate. The distribution of the us is assumed to be
Normal with mean 0 and variances independent of j.
The model provides an estimate of the variance; eijkgroups. The A50value was preferred to the mean age
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are the residual error terms and are assumed to follow
a binomial distribution with variance equivalent to:
ijk( -ijk)
Nijk
Nijk= 1 since individual responses are being modelled.
The possibility that the distribution of the error
terms was extra-binomial was assessed by estimating a
variance inflation factor, o.2 such that, when o.2 = 1,
the distribution is indeed binomial. In all models with
variance estimates not constrained to the binomial
distribution, when a-2 was estimated to be less than 1,
the model was re-run with variance constrained to the
binomial assumption. In addition, normal probability
plots of the study-level standardized residuals were
used to assess whether the assumption of normality of
the us was acceptable, 95 % confidence intervals on
the resulting mean prevalence estimates for each area
were reported.
The force of infection, A, is the per capita rate at
which susceptibles become infected and may vary with
the age of the susceptible [41]. Age-specific forces of
infection were estimated from serological data in two
ways to counter any shortcomings in either technique.
Both methods assume that the incidence ofinfection is
unchanging through time. The first method assumes
that the force of infection is constant over discrete age
classes and a change in the rate at which susceptibles
become infected between age groups (revealed in a
change in the rate of acquisition of serological
markers) is assumed to reflect a change in the force of
infection. The force of infection in age group i, Ai, is
calculated from the difference in the fraction sus-
ceptible between adjoining age groups using the
following expression.
A = -ln [x1+1/x](Aa(
where xi is the proportion susceptible in age-group i
and Aa1 is the difference between the midpoints of age
classes i and i+1 [42]. If seroprevalence falls with
increasing age (due to random or temporal factors),
then the estimate of the force of infection by this
technique will be negative. This is epidemiologically
untenable and in these instances the force of infection
was set to zero over that age difference. The second
technique, developed by Grenfell and Anderson [43],
overcomes this problem by fitting a continuous
function which can be constrained to be equal or
greater than zero to the force of infection by maximum
likelihood. The expected age-serological profile is
simply J-x(a) where x(a) is given by the following
expression [43]
x(a) = exp A(da) (2)
where A(a) takes the form of a polynomial of order
0-4. As the proportion with evidence of previous or
current infection is binomial then the polynomial
form of A(a) providing the best fit to the observed age-
serological profile can be estimated by maximum
likelihood.
Simple model of HBV transmission patterns
We propose a simple compartmental, deterministic
model to describe the transmission dynamics of HBV
similar to that proposed by Anderson and May [41].
Incidence of HBV infection is assumed to be at
endemic equilibrium with respect to time. The rates of
change with respect to age of the proportion of
individuals in a closed population who are susceptible,
x, acutely infected, y, and carriers, c, are described by
the following equations
dx
=- A(a) x,da
d= A(a) x-ay,da
dc = p(a) oy- yc.
(3)
(4)
(5)
Susceptibles are infected at an age-specific, per capita
rate A(a) and move directly into an acute phase. A
proportion of these highly infectious individuals, p(a),
then pass into the carrier class at a rate o-. The
remainder recover and develop immunity to reinfec-
tion at the same rate. Carriers eventually lose
infectiousness and become immune at a rate y.
Immunity is assumed to be lifelong. The above
equations have the initial condition that at birth y(O)
= c(O) = 0 and x(O) = 1, that is, all individuals are
born susceptible. Equations 3-5 can be solved by
assuming that o- is large relative to the other
parameters and consequently that equation 4 is zero,
and an expression for the prevalence of carriers in the
population at age a, c(a) is derived:
c(a) t { A(s) x(s)p(s)f(a -s) ds, (6)
0
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where f(t) is the proportion of carriers who retain the
carrier state t years after infection. For a constant rate
of loss of carriage fit) is
fit) = exp[-yt]. (7)
Although it is likely that the rate of loss of carriage is
not constant, but dependent on a variety of factors
such as age and time since infection. However, there
are not sufficient data to determine this dependency,
and a constant rate is used as a guide to the order of
magnitude of this parameter.
The probability of developing the carrier state, p(a),
declines nonlinearly with increasing age at infection.
This relationship is well described by
p(a) = exp (- 0-645 a0455) (8)
and appears to hold for a wide range of countries,
both developed and developing [18]. With an ap-
propriate function for A(a) the proportion of suscep-
tibles at age a can be calculated from equation 2 and
hence equation 6 can be evaluated given an estimate
of the rate of loss of carriage. The prevalence of
carriers in the population (C) is simply
L
J c(a) n(a) da
C= (9)
J'n(a) da
0
where L is the maximum lifespan and n(a) is the
proportion surviving to age a. Assuming a constant,
per capita natural mortality rate, ,u, the proportion
surviving to age a is exp (-,ta). It follows from equation
2 that
A50
In (0-5) =- A(a) da, (10)
where A50 is, as before, the age at which half the
population have evidence of infection. The model was
solved numberically to yield the prevalence of carriers
(equation 9) for a range of A50 values (equation 10)
and for different functions for the age dependent force
of infection (i.e. exponential decline and constant). To
generate different values of A50 for the exponential
model (y = bo exp (b, a)), the slope (b,) was held
constant and the intercept (bo) was calculated to
achieve the necessary value of A50. The value of b,
was estimated from the median line for the force of
RESULTS
Relationship between the rate of infection and the
prevalence of carriers
The areas studied all had high prevalences of carriers
(prevalence of HBsAg ranged from 3 5-37 3 %) and
had high rates of transmission in childhood (the age at
which half the population was infected ranged from
1 5-18 years). A plot of A50 against the prevalence of
carriers for 16 surveys from areas of high HBV
endemicity revealed a consistent pattern (Fig. 1).
Areas with low values of A50 (high transmission) had,
on average a greater proportion of carriers in the
population than areas with higher values of A50 (low
transmission). This correlation was found to be
statistically significant (Spearmans's Rank Order
Correlation p =-0 6325, t(14) =-3 0558, P <
0 0086). Furthermore, the relationship appears to be
consistent, irrespective of geographical area though
the number of studies is too few to allow a formal
comparison. Residual analysis of a linear regression
model (Bartlett's three group regression [40]) fitted to
the data revealed that the associaton was non-linear
and was further confirmed by comparing the fit of a
linear and a quadratic function to the data by
maximum likelihood. The quadratic model gave a
significantly better fit to the data (likehood ratio test
G = 21i73, x2 test with 1 D.F. P < 0-0005). It is of
interest, that studies from east Asia did not record
higher prevalences of carriers, nor lower values of A50
than surveys from sub-Saharan Africa. We repeated
the analysis using different measures of the prevalence
of carriers, i.e. the prevalence of carriers younger than
20, 15 and 10 years, to avoid possible biases due to
differences between surveys in the upper age limit. The
results were very similar to those presented in Figure
1 for the overall prevalence of carriers and are
therefore not shown.
Incidence of perinatal transmission
The incidence of perinatal transmission depends
primarily on the prevalence of carrier mothers and the
risk of transmission of the virus from a carrier mother
to her infant; acute infections are rare in adults from
high endemicity areas [44].
The prevalence of carrier mothers appears to be
somewhat greater in sub-Saharan Africa and east
Asia than in other developing countries (data sum-
marized in Table 1), although these differences may be
an artifact of biases in the selection of study sites. Ainfection (Figure 2d) by least squares.
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Fig. 1. The correlation between the overall prevalence of
carriers and the estimated age at which 50% of individuals
have evidence of infection, A50, from 16 surveys from highly
endemic areas [26-29, 31-37]. Data from African countries
is denoted by [1, south-east Asian counties by M, and other
high endenicity areas by *.
greater proportion of carrier mothers in east Asia
appear to be HBeAg positive (and therefore highly
infectious) compared with sub-Saharan African
mothers, although the differences are only on the
margins of being statistically significant (Table 2). As
expected, the risk of perinatal transmission is far
greater from HBeAg positive mothers than from
HBeAg negative mothers (comparing Tables 3 and 4).
There appears, however, to be some geographical
variation in the risk of perinatal transmission, most
markedly for HBeAg positive mothers (Table 3). In
east Asia and other countries (the latter are identified
as Developed and Developing in Table 3), the risk of
perinatal transmission from HBeAg positive carrier
mothers is approximately 70-85% whereas the cor-
responding risk to infants in sub-Saharan Africa
appears to be lower (Table 3). This study provides no
evidence of significant geographical differences in the
risk to infants from HBeAg negative, carrier mothers
(Table 4).
Age-specific rates of horizontal transmission
Childhood infection by HBV is primarily due to
horizontal transmission in developing countries, there-
fore the rate or force of infection is a measure of the
rate of horizontal transmission. Age-specific force of
infection patterns estimated from a large number of
surveys from developing countries are summarized in
Figure 2. Figure 2a records the best-fit polynomial
forms of A(a) for seven surveys in sub-Saharan Africa,
and Figure 2b shows similar results for six surveys
from east Asia. In most cases the general pattern of
the force of infection in childhood (under 15) is for it
to decline with increasing age. There appears to be no
substantial differences between the two regions de-
scribed in Figures 2a, b. Estimates of the force of
infection from 16 surveys from highly endemic
developing countries (including the 13 illustrated in
Figs 2a, b), using two different methods are sum-
marized in Figures 2c, d. In Figure 2c, forces of
infection have been estimated for each distinct age-
class, whereas in Figure 2 d, for the same data sets, the
forces of infection were described by polynomial
functions (as in Figs 2a, b). The results from the 16
surveys have been summarized by plotting the
median and upper and lower estimates of the force of
infection for each yearly age class. It is clear that the
methods provide very similar results, with a clear
trend for the force of infection to be greatest in infants
and young children followed by a steady decline
throughout childhood.
Modelling HBV infection patterns
We employed a simple model of the horizontal
transmission of HBV to investigate the importance of
the magnitude and the age-dependent nature of the
force of infection in determining the prevalence of
carriers in a population. The model could capture the
relationship between the age at which half the
population has evidence of infection by HBV and the
overall prevalence of carriers in the community (Fig.
3 a), reproducing the patterns in the observed data for
both a constant and an exponentially decreasing force
of infection.
The model was also used to investigate the influence
of the rate of loss of carriage on HBV infection
patterns. Figure 3b demonstrates that for a constant
force of infection, an average duration of the carrier
state of approximately 30-40 years provides the best
fit to the data.
DISCUSSION
This study clearly shows that in areas of high HBV
endemicity a large proportion of the population is
infected during childhood (i.e. they have low values of
A50), and that there is a nonlinear, inverse relationship
between the age at which half the population has
evidence of HBV infection and the overall prevalence
of carriers in the population. As transmission ofHBV
primarily occurs in childhood we have attempted to
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Table 1. Summary of the prevalence ofHBsAg amongst pregnant women by region*
Sub-Saharan
Africa East Asia Developing
Overall sample sizet 5861 43047 12330
Range of sample sizes 94-3000 1343-17570 300-8575
Mean prevalence: (%) 10-6 9.5 3-6
95 % confidence interval (%) 7-415-0 5-8-15-0 2-1-6-3
* Sub-Saharan Africa includes 2 studies from Senegal [60, 61], 1 each from Ethiopia, Namibia, Kenya and Tanzania [58,
62-64] respectively. East Asia includes 3 studies from Taiwan [13 48 49], 2 studies from Hong Kong [65, 66], 1 from Japan
[67] and 1 from Thailand [68]. Developing refers to data from developing countries which are not in east Asia or sub-Saharan
Africa (this term is also used in Tables 2-4) and includes 2 studies from India [69, 70], and 1 each from Egypt [71], Indonesia
[72] and Kuwait [73].
t The overall sample size is the sum of the sample size from each of the individual surveys within a geographical region. The
same term is used in Tables 2-4.
t The mean prevalence is derived from the model parameter estimate, and the 95 % confidence intervals are calculated from
the standard errors of these estimates. This also applies to Tables 2-4. Study level variance estimate equals 0 204; o- (extra-
binomial variation) estimated to equal 1-04, unconstrained binomial variance used.
Table 2. Summary of the prevalence ofHBeAg amongst HBsAg positive pregnant women in different regions*
Sub-Saharan
Africa East Asia Developing
Overall sample size 243 3774 429
Range of sample sizes 25-116 14-1026 23-322
Mean prevalence: (%) 11 6 45 8 10 5
95% confidence interval (%) 49-24-8 22-2-715 3 1-304
* Data as Table 1, excluding studies not reporting HBeAg. Sub-Saharan Africa includes 2 studies from Senegal [60, 74], and
1 each from Ethiopia [62] and Kenya [58]. East Asia includes 3 studies from Taiwan [48, 49, 75], 2 from Hong Kong [65, 66],
and 1 each from Thailand [68], and Japan [76]. Developing includes 2 studies from India [69, 70], and 1 each from Egypt [71]
and Kuwait [73].
t Study level variance estimate equals 0623; o2 estimated to equal 0 999, constrained binomial variance used, i.e. o-' = 1-0.
Table 3. Summary of the risk to the infant ofperinatal infection over the first year of life from HBeAg positive
mothers by region*
Sub-Saharan
Africa East Asia Developing Developed
Overall sample size 17 352 49 11
Range of sample sizes 4-13 17-94 1-19 4-7
Mean (%) infectedt 27-9 87 5 81 6 73 0
95% confidence interval (%) 9 2-59 6 62 6-96-7 46-7-95 8 25 0-95-5
* Sub-Saharan Africa includes 2 surveys, 1 from Kenya [58] and 1 from Senegal [74]. East Asia includes 5 surveys from
Taiwan [14, 48, 49, 75, 77], 2 from Hong Kong [66, 78], and 1 each from Japan [76] and Thailand [68]. Developed includes
4 surveys from India [69, 70, 79, 80], and 1 each from Egypt [71], and Kuwait [73]. Developed refers to developed countries
and includes 1 survey each from UK [81] and Italy [82].
t The percentage of infants infected (core antibody and/or surface antigen positive) during their first year calculated from
model estimates. Study level variance estimates equals 0-293; o2 estimated to equal 0-949, constrained binomial variance
used, i.e. o- = 10.
quantify the magnitude of perinatal and horizontal
infection. By quantifying these epidemiological vari-
ables we are able to compare the transmission ofHBV
between the main highly endemic areas of east Asia
and sub-Saharan Africa.
Comparing estimates of the age-dependent forces
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Table 4. Summary of the risk to the infant ofperinatal infection over the first year of life from HBeAg
negative, HBsAg positive mothers by region*
Sub-Saharan
Africa East Asia Developing Developed
Overall sample size 85 259 356 116
Range of sample sizes 38-47 15-108 11-186 24-92
Overall % infectedt 8-0 13-2 13-6 7-2
95% confidence interval (%) 1-8-287 2-6-46-2 2-6-48-1 10-8-40-8
* Sub-Saharan Africa includes 1 survey from Kenya [58] and 1 from Senegal [74]. East Asia includes 4 surveys from Taiwan
[14, 48, 75, 77], and 1 survey each from Hong Kong [78], Thailand [68] and Japan [76]. Developing includes 4 surveys from
India [69, 70, 79, 80], and 1 each from Egypt [71] and Kuwait [73]. Developed includes 1 survey from UK [81] and Italy [82].
t The percentage of infants infected (core antibody and/or surface antigen positive) during their first year calculated from
model estimates. Study level variance estimates equals 0-810; o- estimated to equal 0-953, constrained binomial variance
used, i.e. c2 = 10.
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Fig. 2. Age dependence in the force of HBV infection in highly endemic communities. (a) Maximum-likelihood estimates
are based on 7 surveys from sub-Saharan Africa, see text and [43] for details (solid line, Zambia [27]; dotted line, Nairobi
[28]; dashed line, The Gambia [26]; +, Khalawaat, Sudan [29]; A, Saleim, Sudan [29]; x , Senegal [30]; and O, South Africa
[31]). (b) Maximum-likelihood estimates from 6 surveys in east Asia (solid line, Taiwan [32]; dotted line, Kinalaglagan,
Philippines [33]; dashed line, Tagumpay, Philippines [33]; +, Santa Rosa, Philippines [33]; A, Agoho, Philippines [33]; and
x, Shanghai [34]). (c, d) Summarizes age dependent patterns in the force of infection from 16 different surveys, estimated
by two methods (see text for details): discrete age-class (c) [42], and continuous age (d) [43]. In addition to the 13 surveys
shown in (a) and (b), 3 more surveys from other highly endemic populations [35-37] were included. The median (solid line)
and upper and lower bounds (dashed lines) were calculated for each year age group.
of infection in childhood revealed that similar patterns
of HBV infection exist in highly endemic areas.
Typically the force of infection is highest in young
children and declines throughout childhood. The
force of infection is therefore highest in those age
groups that have a high probability of becoming a
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for generating the observed
in the prevalence of carriers
A50. This suggests that the
prevalence of carriers and the value of A50 is primarily
(a) the result of higher average ages at infection in lower
transmission areas resulting in a decrease in the
proportion who become carriers.
The major difference in the epidemiology by HBV
between sub-Saharan Africa and east Asia appears to
be in the incidence of perinatal transmission. A
A greater proportion ofHBsAg positive carriers mothers
appear to be highly infectious (positive for HBeAg) in
10 15 20 east Asia than in sub-Saharan Africa, and there may
be a lower risk of perinatal infection from HBeAg
(b) positive mothers in Africa than in east Asia. The
difference in prevalence of HBeAg among carrier
mothers might be explained by environmental or
genetic differences, or perhaps as a consequence of
perinatal transmission, i.e., infection during the
_ . perinatal period may be associated with a slower rate
A= of loss of HBeAg. The apparent lower risk of perinatal
- -=- transmission from HBeAg positive mothers in Africa
20 may be due to differences in perinatal practices,
10 15 20 though the statistically significant difference may be
(years)
an artifact of the small number of studies with small
,ected proportion of carriers sample sizes. The point needs to be clarified as it
f A50values. The data points would have important implications from the pre-
1. (a) The model was solved
Ia force of infection which vention of perinatal transmission in other parts of the
(dotted line). The rate of loss world.
iral mortality rate, It, was Although east Asian countries appear to have a$0 year-' and 1/50 year-' higher incidence of perinatal transmission they do not
vas solved for different rates have lower values of A50 nor greater prevalences of
fe of carriage was 40 years
Z0 years (dotted) and no loss carriers than sub-Saharan African countries. This
e foce of infection was held may be because horizontal transmission appears to be
the main route by which carriers are infected, even in
east Asia. In pre-vaccination Taiwan, which appears
;ern suggests that highly to have the highest known incidence of perinatal
)n features that allow the transmission, we can estimate that 60%, or more, of
f the virus. The decline in carriers were probably infected horizontally (from
ge may be associated with [18, 32, 48, 49]); in sub-Saharan Africa over 90% of
,line in the prevalence of carriers would be expected to be infected via horizontal
,ith age [32, 45, 46] or a transmission (from [18] and Tables 1-4). The relative
mixing between children. importance of horizontal transmission is supported by
t decline in the force of the results of the model which showed that the
iue to common temporal observed patterns of infection could be generated by a
growth. However, there is model of the horizontal spread of HBV. Although a
g population density in- higher incidence of perinatal infection does not seem
for HBV [47], and it is to influence the overall prevalence of carriers or the
ve time-dependent factors rate of infection to any large extent, it may have
. The results of the simple important implications for the control of HBV, as
ne in the force of infection perinatal infection is more difficult to prevent by
not a necessary condition immunization than horizontal transmission.
decline, between surveys, The importance of carriers to the transmission of
with increasing values of HBV can be roughly estimated by comparing the
relationship between the duration of the carrier state and the infectiousness of
A ~ ~ N
A\
A-
A
A
A
A
- --- __ -
-
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carriers with the longevity of the acute stage and the
infectiousness of the acutely infected individuals.
Serological data from longitudinal studies of carriers
suggests that HBsAg is lost from a proportion of
carriers, and that the mean duration of the carrier
state (in all carriers) is somewhere in the range of
20-200 years [10, 50-53]. The results of the model
provide an alternative method for estimating the rate
of loss of carriage, and suggest that the mean duration
of the carrier state is 30-40 years. The relative
infectiousness of carriers can be estimated from
perinatal transmission studies of acutely and chroni-
cally infected mothers. Serological data, mainly from
developed countries, suggest that acutely infected
mothers transmit HBV to 70-75% of their infants
within 3 months of birth [39, 54, 55], whereas only
0-27% of carrier mothers infect their infants in a
similar time period [55-58]. Comparing the mean
proportion of infants infected from acutely and
chronically infected mothers suggests that on average
(i.e. including both HBeAg positive and negative
mothers) mothers in the acute phase are approxi-
mately 7 times as infectious as chronically infected
mothers. Hence, the lower infectiousness of carriers is
more than offset by the longer periods of infectious-
ness of carriers compared to acutes (30-40 years
compared to about 3 months [22]), and they are
therefore more important to the spread of HBV.
Areas with a low average age at infection, ir-
respective of the route of transmission, will, on
average, have high prevalences of carriers because of
the age-dependent nature of becoming a carrier. These
areas can therefore be expected to have a higher force
of infection (as carriers are responsible for the
majority of transmission) and hence a lower average
age at infection. This positive feedback probably
accounts for the very high variation in endemicity
among different localities and will tend to produce
hyper-endemic regions if the conditions for childhood
infection are met. If, however, childhood infection is
prevented by mass immunization of infants, the
decrease in the rate of generation of new carriers will
be greater than linear because of the decline with
increasing age in the risk of a carrier. Mass immuniz-
ation will reduce the circulation of virus in the
community such that the average age at infection in
those not successfully immunized will increase (as seen
in other childhood infections [59]), hence reducing
their chances of becoming infected (Fig. 2), and, if
infected, of becoming carriers. In addition, even if
vaccination does not induce life-long immunity,
delaying infection in young children will itself reduce
the numbers of carriers in a population. As many
countries are considering, or have already begun,
mass immunization programmes, the quantitative
aspects of these programmes on the transmission
dynamics of HBV require urgent attention.
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